JP2021535204A5 - - Google Patents

Info

Publication number
JP2021535204A5
JP2021535204A5 JP2021533377A JP2021533377A JP2021535204A5 JP 2021535204 A5 JP2021535204 A5 JP 2021535204A5 JP 2021533377 A JP2021533377 A JP 2021533377A JP 2021533377 A JP2021533377 A JP 2021533377A JP 2021535204 A5 JP2021535204 A5 JP 2021535204A5
Authority
JP
Japan
Prior art keywords
composition according
modified
scn1a
nucleic acid
oligonucleotide
Prior art date
Application number
JP2021533377A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020041348A5 (https=
JP2021535204A (ja
JP7476199B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/047313 external-priority patent/WO2020041348A1/en
Publication of JP2021535204A publication Critical patent/JP2021535204A/ja
Publication of JPWO2020041348A5 publication Critical patent/JPWO2020041348A5/ja
Publication of JP2021535204A5 publication Critical patent/JP2021535204A5/ja
Priority to JP2024066672A priority Critical patent/JP7851349B2/ja
Application granted granted Critical
Publication of JP7476199B2 publication Critical patent/JP7476199B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021533377A 2018-08-20 2019-08-20 Ｓｃｎ１ａ脳症の治療のためのｓｃｎ２ａを標的とするアンチセンスオリゴヌクレオチド Active JP7476199B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024066672A JP7851349B2 (ja) 2018-08-20 2024-04-17 Ｓｃｎ１ａ脳症の治療のためのｓｃｎ２ａを標的とするアンチセンスオリゴヌクレオチド

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862765344P 2018-08-20 2018-08-20
US62/765,344 2018-08-20
PCT/US2019/047313 WO2020041348A1 (en) 2018-08-20 2019-08-20 Antisense oligonucleotides targeting scn2a for the treatment of scn1a encephalopathies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024066672A Division JP7851349B2 (ja) 2018-08-20 2024-04-17 Ｓｃｎ１ａ脳症の治療のためのｓｃｎ２ａを標的とするアンチセンスオリゴヌクレオチド

Publications (4)

Publication Number Publication Date
JP2021535204A JP2021535204A (ja) 2021-12-16
JPWO2020041348A5 JPWO2020041348A5 (https=) 2022-08-03
JP2021535204A5 true JP2021535204A5 (https=) 2022-08-03
JP7476199B2 JP7476199B2 (ja) 2024-04-30

Family

ID=69591162

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021533377A Active JP7476199B2 (ja) 2018-08-20 2019-08-20 Ｓｃｎ１ａ脳症の治療のためのｓｃｎ２ａを標的とするアンチセンスオリゴヌクレオチド

Country Status (9)

Country Link
US (2) US11939582B2 (https=)
EP (1) EP3840733A4 (https=)
JP (1) JP7476199B2 (https=)
CN (1) CN113329739B (https=)
AU (1) AU2019325255A1 (https=)
BR (1) BR112021003224A2 (https=)
CA (1) CA3110211A1 (https=)
EA (1) EA202190581A1 (https=)
WO (1) WO2020041348A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3359685B1 (en) 2015-10-09 2026-01-28 University Of Southampton Modulation of gene expression for deregulated protein expression
EP3933041B1 (en) 2015-12-14 2024-01-31 Cold Spring Harbor Laboratory Antisense oligomers for treatment of autosomal dominant retardation
SG11202001590RA (en) 2017-08-25 2020-03-30 Stoke Therapeutics Inc Antisense oligomers for treatment of conditions and diseases
US12060558B2 (en) 2018-05-04 2024-08-13 Stoke Therapeutics, Inc. Methods and compositions for treatment of cholesteryl ester storage disease
KR20210134003A (ko) 2019-02-27 2021-11-08 스톡 테라퓨틱스, 인크. 병태 및 질환의 치료를 위한 안티센스 올리고머
WO2021174036A1 (en) * 2020-02-28 2021-09-02 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating scn1a expression
BR112022022889A2 (pt) 2020-05-11 2023-04-04 Stoke Therapeutics Inc Oligômeros antissentido de opa1 para tratamento de condições e doenças
CN116368227A (zh) * 2020-07-22 2023-06-30 弗洛里神经科学与心理健康研究所 用于治疗与scn2a中功能失去突变相关的障碍的组合物和方法
IL300258A (en) * 2020-08-07 2023-03-01 Ionis Pharmaceuticals Inc Compounds and methods for modulating SCN2A
EP4155402A1 (en) 2021-09-22 2023-03-29 Royal College of Surgeons in Ireland Modulation of microrna-335 for the treatment of sodium channelopathies
EP4562020A2 (en) * 2022-07-29 2025-06-04 Stoke Therapeutics, Inc. Compounds for treatment of conditions and diseases
MX2025013084A (es) * 2023-05-03 2026-02-03 Stoke Therapeutics Inc Compuestos y métodos para tratar sujetos humanos

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US5367066A (en) 1984-10-16 1994-11-22 Chiron Corporation Oligonucleotides with selectably cleavable and/or abasic sites
FR2575751B1 (fr) 1985-01-08 1987-04-03 Pasteur Institut Nouveaux nucleosides de derives de l'adenosine, leur preparation et leurs applications biologiques
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
AU598946B2 (en) 1987-06-24 1990-07-05 Howard Florey Institute Of Experimental Physiology And Medicine Nucleoside derivatives
US5175273A (en) 1988-07-01 1992-12-29 Genentech, Inc. Nucleic acid intercalating agents
US5134066A (en) 1989-08-29 1992-07-28 Monsanto Company Improved probes using nucleosides containing 3-dezauracil analogs
US5130302A (en) 1989-12-20 1992-07-14 Boron Bilogicals, Inc. Boronated nucleoside, nucleotide and oligonucleotide compounds, compositions and methods for using same
US5859221A (en) 1990-01-11 1999-01-12 Isis Pharmaceuticals, Inc. 2'-modified oligonucleotides
US5587470A (en) 1990-01-11 1996-12-24 Isis Pharmaceuticals, Inc. 3-deazapurines
US5459255A (en) 1990-01-11 1995-10-17 Isis Pharmaceuticals, Inc. N-2 substituted purines
US6005087A (en) 1995-06-06 1999-12-21 Isis Pharmaceuticals, Inc. 2'-modified oligonucleotides
US5681941A (en) 1990-01-11 1997-10-28 Isis Pharmaceuticals, Inc. Substituted purines and oligonucleotide cross-linking
US5457191A (en) 1990-01-11 1995-10-10 Isis Pharmaceuticals, Inc. 3-deazapurines
BR9106702A (pt) 1990-07-27 1993-06-08 Isis Pharmaceuticals Inc Analogo de oligonucleotideos e processos para modular a producao de uma proteina por um organismo e para tratar um organismo
US5432272A (en) 1990-10-09 1995-07-11 Benner; Steven A. Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
US5948903A (en) 1991-01-11 1999-09-07 Isis Pharmaceuticals, Inc. Synthesis of 3-deazapurines
US5594121A (en) 1991-11-07 1997-01-14 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified purines
TW393513B (en) 1991-11-26 2000-06-11 Isis Pharmaceuticals Inc Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
US5484908A (en) 1991-11-26 1996-01-16 Gilead Sciences, Inc. Oligonucleotides containing 5-propynyl pyrimidines
AU3222793A (en) 1991-11-26 1993-06-28 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
US5434257A (en) 1992-06-01 1995-07-18 Gilead Sciences, Inc. Binding compentent oligomers containing unsaturated 3',5' and 2',5' linkages
US5502177A (en) 1993-09-17 1996-03-26 Gilead Sciences, Inc. Pyrimidine derivatives for labeled binding partners
US5457187A (en) 1993-12-08 1995-10-10 Board Of Regents University Of Nebraska Oligonucleotides containing 5-fluorouracil
US5596091A (en) 1994-03-18 1997-01-21 The Regents Of The University Of California Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
US5525711A (en) 1994-05-18 1996-06-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pteridine nucleotide analogs as fluorescent DNA probes
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
USRE44779E1 (en) 1997-03-07 2014-02-25 Santaris Pharma A/S Bicyclonucleoside and oligonucleotide analogues
US6770748B2 (en) 1997-03-07 2004-08-03 Takeshi Imanishi Bicyclonucleoside and oligonucleotide analogue
US7572582B2 (en) 1997-09-12 2009-08-11 Exiqon A/S Oligonucleotide analogues
AU9063398A (en) 1997-09-12 1999-04-05 Exiqon A/S Oligonucleotide analogues
US6794499B2 (en) 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
WO2000063364A2 (en) 1999-04-21 2000-10-26 American Home Products Corporation Methods and compositions for inhibiting the function of polynucleotide sequences
EP1178999B1 (en) 1999-05-04 2007-03-14 Santaris Pharma A/S L-ribo-lna analogues
US6525191B1 (en) 1999-05-11 2003-02-25 Kanda S. Ramasamy Conformationally constrained L-nucleosides
US20030175906A1 (en) 2001-07-03 2003-09-18 Muthiah Manoharan Nuclease resistant chimeric oligonucleotides
US20030158403A1 (en) 2001-07-03 2003-08-21 Isis Pharmaceuticals, Inc. Nuclease resistant chimeric oligonucleotides
WO2003060525A1 (en) 2002-01-17 2003-07-24 Evotec Neurosciences Gmbh Diagnostic and therapeutic use of the voltage-gated ion channel scn2a for neurodegenerative diseases
AU2003268096A1 (en) * 2002-08-14 2004-03-03 Pharmacia Corporation ANTISENSE MODULATION OF Nav1.3 EXPRESSION
CA2504694C (en) 2002-11-05 2013-10-01 Isis Pharmaceuticals, Inc. Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
US8604183B2 (en) 2002-11-05 2013-12-10 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
US7511131B2 (en) 2002-11-13 2009-03-31 Genzyme Corporation Antisense modulation of apolipoprotein B expression
US6673661B1 (en) 2002-12-20 2004-01-06 Taiwan Semiconductor Manufacturing Co., Ltd. Self-aligned method for forming dual gate thin film transistor (TFT) device
WO2004106356A1 (en) 2003-05-27 2004-12-09 Syddansk Universitet Functionalized nucleotide derivatives
EP1661905B9 (en) 2003-08-28 2012-12-19 IMANISHI, Takeshi Novel artificial nucleic acids of n-o bond crosslinkage type
WO2005027962A1 (en) 2003-09-18 2005-03-31 Isis Pharmaceuticals, Inc. 4’-thionucleosides and oligomeric compounds
US20100088778A1 (en) 2005-06-16 2010-04-08 John Charles Mulley Methods of Treatment, and Diagnosis of Epilepsy by Detecting Mutations in the SCN1A Gene
JP5342881B2 (ja) 2006-01-27 2013-11-13 アイシス ファーマシューティカルズ， インコーポレーテッド ６−修飾された二環式核酸類似体
US7569686B1 (en) 2006-01-27 2009-08-04 Isis Pharmaceuticals, Inc. Compounds and methods for synthesis of bicyclic nucleic acid analogs
US7666854B2 (en) 2006-05-11 2010-02-23 Isis Pharmaceuticals, Inc. Bis-modified bicyclic nucleic acid analogs
AU2007249349B2 (en) 2006-05-11 2012-03-08 Isis Pharmaceuticals, Inc. 5'-Modified bicyclic nucleic acid analogs
US20100190837A1 (en) 2007-02-15 2010-07-29 Isis Pharmaceuticals, Inc. 5'-Substituted-2-F' Modified Nucleosides and Oligomeric Compounds Prepared Therefrom
EP2170917B1 (en) 2007-05-30 2012-06-27 Isis Pharmaceuticals, Inc. N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
EP2173760B2 (en) 2007-06-08 2015-11-04 Isis Pharmaceuticals, Inc. Carbocyclic bicyclic nucleic acid analogs
US20110046206A1 (en) 2007-06-22 2011-02-24 Isis Pharmaceuticals, Inc. Double strand compositions comprising differentially modified strands for use in gene modulation
CA2692579C (en) 2007-07-05 2016-05-03 Isis Pharmaceuticals, Inc. 6-disubstituted bicyclic nucleic acid analogs
WO2009023855A2 (en) 2007-08-15 2009-02-19 Isis Pharmaceuticals, Inc. Tetrahydropyran nucleic acid analogs
US8546556B2 (en) 2007-11-21 2013-10-01 Isis Pharmaceuticals, Inc Carbocyclic alpha-L-bicyclic nucleic acid analogs
WO2009100320A2 (en) 2008-02-07 2009-08-13 Isis Pharmaceuticals, Inc. Bicyclic cyclohexitol nucleic acid analogs
WO2010036698A1 (en) 2008-09-24 2010-04-01 Isis Pharmaceuticals, Inc. Substituted alpha-l-bicyclic nucleosides
AU2009321477A1 (en) 2008-11-27 2010-06-03 Howard Florey Institute Modulation of an ion channel or receptor
EP2462153B1 (en) 2009-08-06 2015-07-29 Isis Pharmaceuticals, Inc. Bicyclic cyclohexose nucleic acid analogs
WO2011123621A2 (en) 2010-04-01 2011-10-06 Alnylam Pharmaceuticals Inc. 2' and 5' modified monomers and oligonucleotides
US10913767B2 (en) 2010-04-22 2021-02-09 Alnylam Pharmaceuticals, Inc. Oligonucleotides comprising acyclic and abasic nucleosides and analogs
WO2011163499A2 (en) * 2010-06-23 2011-12-29 Opko Curna, Llc Treatment of sodium channel, voltage-gated, alpha subunit (scna) related diseases by inhibition of natural antisense transcript to scna
WO2015106128A2 (en) 2014-01-09 2015-07-16 Alnylam Pharmaceuticals, Inc. MODIFIED RNAi AGENTS
WO2015109034A1 (en) 2014-01-14 2015-07-23 The Trustees Of Columbia University In The City Of New York Biological pacemakers incorporating hcn2 and skm1 genes
US20170044540A1 (en) 2014-04-22 2017-02-16 Mina Therapeutics Limited Sarna compositions and methods of use
GB201410693D0 (en) 2014-06-16 2014-07-30 Univ Southampton Splicing modulation
CA2958524A1 (en) 2014-08-20 2016-02-25 Lifesplice Pharma Llc Splice modulating oligonucleotides and methods of use thereof
CN107109411B (zh) 2014-10-03 2022-07-01 冷泉港实验室 核基因输出的定向增加
JP7049249B2 (ja) 2015-12-14 2022-04-06 コールド スプリング ハーバー ラボラトリー 中枢神経系疾患の処置のための組成物および方法
EP3933041B1 (en) 2015-12-14 2024-01-31 Cold Spring Harbor Laboratory Antisense oligomers for treatment of autosomal dominant retardation
WO2018064498A1 (en) 2016-09-30 2018-04-05 Pairnomix, Llc Methods of treating epilepsy and related neurological conditions
DK3548033T3 (da) 2016-11-28 2024-07-15 Praxis Prec Medicines Inc Forbindelser og deres fremgangsmåde til anvendelse
JP7312749B2 (ja) 2017-08-04 2023-07-21 スカイホーク・セラピューティクス・インコーポレーテッド スプライシングをモジュレートする方法および組成物
SG11202001590RA (en) 2017-08-25 2020-03-30 Stoke Therapeutics Inc Antisense oligomers for treatment of conditions and diseases
WO2019232209A1 (en) 2018-05-30 2019-12-05 Praxis Precision Medicines, Inc. Ion channel modulators

Similar Documents

Publication Publication Date Title
JP2021535204A5 (https=)
JP7037681B2 (ja) Ｔｍｐｒｓｓ６発現を調節するための化合物及び方法
CA2730203C (en) Complement antagonists and uses thereof
JP2021104035A (ja) アタキシン２の発現を調節するための組成物
US9796976B2 (en) Methods and compositions for modulating alpha-1 antitrypsin expression
US20250066792A1 (en) Compounds and methods for modulation of dystrophia myotonica-protein kinase (dmpk) expression
JP7476199B2 (ja) Ｓｃｎ１ａ脳症の治療のためのｓｃｎ２ａを標的とするアンチセンスオリゴヌクレオチド
AU2012347765B2 (en) Non-ionic, low osmolar contrast agents for delivery of antisense oligonucleotides and treatment of disease
US20220000901A1 (en) Compounds and methods for modulating angiotensinogen expression
CN102625809A (zh) 亨廷顿表达的调节
JP2019088329A (ja) 成長ホルモン受容体のモジュレータ
KR20210008498A (ko) Fxi 발현을 감소시키기 위한 화합물 및 방법
JPWO2020041348A5 (https=)
CN114072501A (zh) 抗c9orf72寡核苷酸及相关方法
US20250186508A1 (en) Par2 modulation to alter myelination
JP7851349B2 (ja) Ｓｃｎ１ａ脳症の治療のためのｓｃｎ２ａを標的とするアンチセンスオリゴヌクレオチド
US20260053915A1 (en) Combination of radiation/chemotherapy, pd-1 inhibitor and fatty acid synthase inhibitor
JP7016184B2 (ja) ｍｉｃｒｏＲＮＡ－２１を標的とした変形性関節症による疼痛の緩和
RU2858547C2 (ru) Композиции для модулирования экспрессии sod-1
EP4677090A2 (en) Compositions and methods for modulating c3
WO2011105901A2 (en) Antagonists of complement component 9 (c9) and uses thereof
WO2022016097A1 (en) G9a inhibition decreases stress-induced and dependence-induced escalation of alcohol drinking
WO2011105900A2 (en) Antagonists of complement component 8-alpha (c8-alpha) and uses thereof